Navigation Links
Vanda Pharmaceuticals Reports First Quarter 2012 Results
Date:5/8/2012

ion for the first quarter of 2011.Total operating expenses for the first quarter of 2012 were $16.5 million, compared to $7.5 million for the first quarter of 2011.  The primary driver of the higher expenses in the first quarter of 2012 was the ongoing support of the tasimelteon Non-24 and MDD clinical studies. 

Vanda recorded a net loss of $8.0 million for the first quarter of 2012, compared to net income of $0.1 million for the first quarter of 2011.  Diluted net loss per share for the first quarter of 2012 was $0.28, compared to diluted net income of $0.00 per share for the first quarter of 2011. First Quarter 2012 Key Financial Figures(1)Three Months EndedMarch 31December 31(in thousands, except per share amounts)20122011  Change ($)Change (%)Total revenues

$
8,141$
8,370$
(229)(3%)Research & development  expenses

12,18010,5561,62415%General & administrative expenses

3,9093,34556417%Non-cash stock-based compensation(2)

1,4021,318846%Loss before tax benefit

(7,962)(5,809)(2,153)(37%)Tax benefit

-(286)286100%Net loss

(7,962)(5,523)(2,439)(44%)Diluted net loss per share

$
(0.28)$
(0.20)$
(0.08)(40%)Select Cash Flow Data(1)  

Three Months EndedMarch 31March 31(in thousands)20122011Net cash provided by (used in)Operating activities

$
(8,690)$
(3,264)Investing activities

28,86113,225Financing activities

--Select Balance Sheet Data(1) March 31December 31March 31(in thousands)201220112011Total cash and marketable securities

$
57,250$
7,896$
94,555(1) Unaudited(2) Non-cash stock-based compensation is allocated to both Research & development and General & administrative expenses OPERATIONAL HIGHLIGHTSOn January 26, 2012, Vanda announced that initial clinical data in the RESET study revealed the potential of tasimelteon to reset the body clock in Non-
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
4. Vanda Presents Phase III Iloperidone Efficacy Data
5. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
6. Vanda Pharmaceuticals Provides Update on Iloperidone
7. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
8. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
9. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
10. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
11. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 2014   Intarcia Therapeutics, Inc. today announced ... 3 clinical trials for ITCA 650 (exenatide, delivered continuously ... mini-pump). The first trial, FREEDOM-1, was a placebo-controlled, double-blind ... safety of ITCA 650 in patients with type 2 ... be significantly superior to placebo for both 40 mcg ...
(Date:10/1/2014)... , Oct. 1, 2014 The ... available. Interested parties can learn about the ... Health is supporting the health care continuum ... . Photo- http://photos.prnewswire.com/prnh/20140930/149504-INFO ... financials and the chief executive officer,s letter ...
(Date:10/1/2014)... , Oct. 1, 2014  Dyadic International, ... with patented and proprietary technology used to develop ... bioenergy, bio-based chemicals, biopharmaceuticals, and industrial enzymes industries, ... payment from Abengoa Bioenergy for commercial scale production ... biomass into ethanol, developed under Abengoa,s license agreement ...
Breaking Medicine Technology:Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Cardinal Health 2014 Digital Report to Shareholders Now Available 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3
... May 3, 2012   Kensey Nash Corporation (Nasdaq: KNSY ... with Royal DSM (DSM) (NYSE Euronext: DSM KON), under which DSM ... Nash through a cash tender offer, followed by a merger with ... "We are very pleased to have entered into the ...
... CAESAREA, Israel, May 2, 2012 Angioslide ... announced that it has received FDA 510(K) clearance for ... Disease in below the knee (BTK) vasculature.  The new ... potential use of PROTEUS technology.   Angioslide,s ...
Cached Medicine Technology:Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 2Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 3Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 4Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 5Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 6Angioslide Announces FDA 510(K) Clearance of PROTEUS(TM) Below The Knee Device 2
(Date:10/1/2014)... BOSTON (October 1, 2014) Despite a policy ... with developmental disabilities, this vulnerable population continues to ... of The Journal of the American Dental ... Medicine and Tufts University School of Dental Medicine ... factors influencing at-home oral care provided by caregivers ...
(Date:10/1/2014)... October 01, 2014 Familylifeinsurancequotes.org has ... life insurance for senior citizens. , Senior citizens ... will now sell coverage to seniors who are over ... be purchased without taking a medical examination. , Term ... online and senior clients can qualify. Having life insurance ...
(Date:10/1/2014)... Insuranceragents.info has released a new blog post ... for vulnerable family members. , Life insurance plans provide ... the family should always carry a life insurance policy ... rest of the family. , Clients can choose ... from temporary coverage or from a permanent policy. No ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog post explaining ... smokers. , Smoking will always have a negative impact ... best method to find affordable coverage. Insurance brokerage websites ... , Whole life insurance premiums will be fixed ... coverage is permanent, the initial rates are very ...
(Date:10/1/2014)... Phoseon Technology, the pioneer in developing ... business worldwide. This rapid growth includes increased hiring for ... efforts. The company has experienced average annual growth rates ... this growth to continue in the future as new ... , “We are very pleased that UV ...
Breaking Medicine News(10 mins):Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2
... 28 Following the feature of the UltraPulse CO2 fractional laser ... Show , The Insider will also be featuring the ... and Trae Berns were interviewed today by The Insider . ... they have lived with for 20 years. The girls also discussed ...
... 28 Nuvilex, Inc. (OTC Bulletin Board: NVLX), an ... Kentrist 41 Direct, Inc. (CK41), the Company,s joint venture ... has updated its product launch plans. The previously announced ... Mr. Savage, CK41,s new Chief Executive Officer, to impart ...
... 28 Air Products, (NYSE: APD ... at www.airproducts.com/Responsibility/2009CRAR/index.asp . "In these trying times ... improved sustainability performance for our customers and our ... Products, chairman, president and chief executive officer. ...
... the American Heart Association, "silent" or "hidden" heart attacks ... are left untreated.Saint Francis Hospital in Evanston, Ill. has ... offer a new test for chest pain patients that ... The uniqueness of the new test lies in a ...
... Monday, June 1, 20091:30 to 2:30 p.m. Rooftop garden offers patients quiet haven, conservatory features ... Aurora St. Luke,s Medical Center is dedicating the Vince, ... Funds Healing Garden and the Agnes and, ... Monday, June 1, 1:30 to 2:30 p.m., WHERE: ...
... in Health Affairs finds that a Massachusetts ... has resulted in higher costs. This predictable result confirms ... must be a part of national health reform, said ... that reform is unaffordable without a public option like ...
Cached Medicine News:Health News:Miracle Treatment for Burn Scars as Seen on Today Show Will Also Be Featured on The Insider Tonight 2Health News:Miracle Treatment for Burn Scars as Seen on Today Show Will Also Be Featured on The Insider Tonight 3Health News:Nuvilex Gets Update from CK41 on purEffect(TM) Launch Plan 2Health News:Nuvilex Gets Update from CK41 on purEffect(TM) Launch Plan 3Health News:Nuvilex Gets Update from CK41 on purEffect(TM) Launch Plan 4Health News:Air Products' 2009 Corporate Responsibility Report Now Available 2Health News:Finding Hidden Heart Attacks: Saint Francis Hospital is First in Illinois to Detect Hidden Heart Attacks With New Technology 2Health News:Health Affairs Report On Mass. Mandatory Insurance Law Confirms: Strong Public Option Must Be Included in National Health Reform 2Health News:Health Affairs Report On Mass. Mandatory Insurance Law Confirms: Strong Public Option Must Be Included in National Health Reform 3
The MPM-1 offers a broad range of functions to attain new levels of parenchymal and ventricular monitoring through fiberoptic technology at the source....
... The Polaris system delivers the ... cost effective and easy to use, ... level of precision measurement with unprecedented ... both active and passive tools, the ...
Penfield Dissector #4...
Leroy scalp clips, sterile, disposable, plastic, infant size, ten clips/package....
Medicine Products: